Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence

PURPOSE: To analyse outcomes of innovator ranibizumab (IRM) (Lucentis) and biosimilar ranibizumab (BRM) (Razumab) in Indian eyes with neovascular age-related macular degeneration (nAMD). METHODS: Retrospective observational study in nAMD patients, who were treated with IRM or BRM (3 loading doses fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Debdulal, Mondal, Soumen, Boral, Subhendu, Das, Arnab, Sinha, Tushar Kanti, Majumdar, Saptorshi, Bhattacharya, Ranabir, Maitra, Ritobroto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097398/
https://www.ncbi.nlm.nih.gov/pubmed/37064960
http://dx.doi.org/10.2147/OPTH.S407219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097398/
https://www.ncbi.nlm.nih.gov/pubmed/37064960
http://dx.doi.org/10.2147/OPTH.S407219

Ejemplares similares